Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030


Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends

The global metastatic lung adenocarcinoma treatment market size is anticipated to reach USD 9.3 billion by 2030, growing at a CAGR of 11.3% from 2024 to 2030, according to a report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights
  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2023, the chemotherapy segment accounted for the largest revenue share of 33.2% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 64.3% in 2023. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Outlook
2.2.2. End Use Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. The increasing incidence of lung cancer
3.2.1.2. Advancements in targeted therapies and immunotherapies
3.2.1.3. The growing emphasis on personalized medicine
3.2.1.4. The rising demand for early detection and screening programs
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatments
3.2.2.2. Limited availability of skilled healthcare professionals
3.3. Metastatic Lung Adenocarcinoma Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatments Estimates & Trend Analysis
4.1. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Dashboard
4.2. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
4.3. Global Metastatic Lung Adenocarcinoma Treatment Market by Treatment, Revenue
4.4. Chemotherapy
4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Immunotherapy
4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Radiation Therapy
4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Other
4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis
5.1. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Dashboard
5.2. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
5.3. Global Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Specialty Clinics
5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other
5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis by Treatments, and End Use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key company market share analysis, 2023
7.2.3. Pfizer
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Eli Lilly and Company
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. AstraZeneca
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bristol-Myers Squibb Company
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Boehringer Ingelheim International GmbH
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Novartis AG
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Merck KGaA (EMD Serono)
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. F. Hoffmann-La Roche
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. GSK Plc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. AbbVie Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings